Morgan Stanley Impel Pharmaceuticals Inc Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.96 - $4.1 $136 - $582	-142 Reduced 6.63%	2,000 $2,000
Q4 2022 Feb 14, 2023	SELL	$2.59 - $4.0 $24,286 - $37,508	-9,377 Reduced 81.4%	2,142 $8,000
Q3 2022 Nov 14, 2022	SELL	$5.78 - $9.32 $23,969 - $38,650	-4,147 Reduced 26.47%	11,519 $55,000
Q2 2022 Oct 27, 2022	BUY	$5.83 - $10.12 $26,549 - $46,086	4,554 Added 40.98%	15,666 $145,000
Q2 2022 Aug 15, 2022	BUY	$5.83 - $10.12 $26,549 - $46,086	4,554 Added 40.98%	15,666 $145,000

Q1 2022 Oct 27, 2022	SELL	$5.86 - $9.85 $26,686 - $44,856	-4,554 Reduced 29.07%	11,112 $70,000
Q1 2022 May 13, 2022	SELL	$5.86 - $9.85 $5,666 - $9,524	-967 Reduced 8.01%	11,112 $70,000
Q4 2021 Feb 14, 2022	BUY	$8.33 - $12.14 $47,730 - $69,562	5,730 Added 90.25%	12,079 $105,000
Q3 2021 Nov 15, 2021	BUY	$8.38 - $26.13 $53,204 - $165,899	6,349 New	6,349 $78,000

14.4K

Ticker IMPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,738,800
Market Cap $475K
Description
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The c...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.